SERUM IMMUNOSUPPRESSIVE ACIDIC PROTEIN AND NATURAL KILLER CELL ACTIVITY IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA BEFORE AND AFTER NEPHRECTOMY
- 1 September 2000
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 164, 673-675
- https://doi.org/10.1097/00005392-200009010-00013
Abstract
To our knowledge the impact of nephrectomy on stage M1 renal cell carcinoma remains to be determined. We previously reported that nephrectomy is beneficial in patients with elevated serum C-reactive protein before treatment, and those in whom nadir C-reactive protein decreases postoperatively to within the normal range may expect longer survival when surgery is combined with postoperative immunotherapy. In this study we determine the effect of nephrectomy on the immune response in patients with metastatic renal cell carcinoma. We retrospectively reviewed the records of 40 patients with metastatic renal cell carcinoma diagnosed at our institution between 1986 and 1999. These patients underwent nephrectomy before cytokine therapy with interferon. Before and after nephrectomy we measured serum C-reactive protein, serum immunosuppressive acidic protein and peripheral blood natural killer cell activity. In 15 patients with pretreatment serum C-reactive protein within the normal range (less than 1 ng./ml.) there was no significant difference before and after nephrectomy in the serum immunosuppressive acidic protein level or natural killer cell activity (p = 0.4587 and 0.3892, respectively). On the other hand, in 25 patients with serum C-reactive protein elevated before treatment to 1 ng./ml. or greater serum immunosuppressive acidic protein decreased significantly and natural killer cell activity increased significantly after cytoreductive surgery (p = 0.0002 and 0.0286, respectively). Our study implies that nephrectomy may be beneficial in patients with elevated serum C-reactive protein before treatment. Further evaluation by a prospective study is needed to make a definitive conclusion.Keywords
This publication has 16 references indexed in Scilit:
- SERUM C-REACTIVE PROTEIN LEVEL AND THE IMPACT OF CYTOREDUCTIVE SURGERY IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMAJournal of Urology, 1999
- Kidney cancerThe Lancet, 1998
- Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell CarcinomaNew England Journal of Medicine, 1998
- CYTOREDUCTIVE SURGERY BEFORE HIGH DOSE INTERLEUKIN-2 BASED THERAPY IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMAJournal of Urology, 1997
- Cytoreductive Surgery for Stage IV Renal Cell CarcinomaJournal of Urology, 1995
- Prognostic Factors for Survival in Patients with Metastatic Renal Cancer Treated with Biological Response ModifiersJournal of Urology, 1995
- Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.Journal of Clinical Oncology, 1995
- Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up.Journal of Clinical Oncology, 1993
- Metastatic Renal Cancer Treated with Interleukin-2 and Lymphokine-Activated Killer CellsAnnals of Internal Medicine, 1988
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985